WW · Ww International, Inc.

NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) - WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced the following updates to the composition of its Board of Directors’ standing committees following the appointments of Lisa Gavales and Sue Gove as independent directors: Audit Committee: Gene Davis (Chair), Sue Gove, Carney Hawks and Nikolaj Sjoqvist; Compensation and Benefits Committee: Carney Hawks (Chair), Gene Davis and Lisa Gavales; Nominating and Corporate Governance Committee: Nikolaj Sjoqvist (Chair), Gene Davis and Sue Gove; and Strategy and Finance Committee: Gene Davis (Chair), Lisa Gavales, Carney Hawks, Mike Mason and Nikolaj Sjoqvist. Office of the CEO Update As previously announced, the Board established a Transition Committee to oversee the Office of the CEO, which comprises Felicia DellaFortuna, the Company’s Chief Financial Officer, and Jon Volkmann, the Company’s

New, Independent Directors Bring Deep Consumer, Digital and Turnaround Expertise to Support Strategic Transformation NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) - WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced that it has appointed accomplished executives, Lisa Gavales and Sue Gove, as independent members of the Company’s Board of Directors, effective April 7, 2026. Ms. Gavales and Ms. Gove will serve as directors until the Company’s 2026 annual meeting of shareholders and are expected to stand for election at the annual meeting. Following these appointments, the Board consists of six directors, all of whom are independent. Lisa Gavales and Sue Gove are highly regarded consumer brand leaders with distinct expertise that will enhance the Board as Weight Watchers advances its next phase of growth. Ms. Gavales is a consumer and retail executive with a proven track record of building

Office of the CEO Established to Oversee Business Operations Board Forms Transition Committee and Commences CEO Search NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) - WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced leadership and governance changes, including the establishment of an Office of the CEO and the formation of a new Transition Committee of the Board of Directors (“the Board”). These actions follow Tara Comonte’s departure from the Company, effective March 31, 2026. The Company’s Board of Directors has initiated a comprehensive search for a permanent successor with the support of a leading executive search firm. During the transition period, the Office of the CEO will oversee business operations and execution of the Company’s strategy. The Office of the CEO comprises Felicia DellaFortuna, Chief Financial Officer, and Jon Volkmann, Chief Operations Officer. In addition, the Board is

Through expanded collaboration with Novo Nordisk, eligible Med+ members can now save up to $1,200 per year on Wegovy®, increasing affordable access to FDA-approved GLP-1 treatment leveraging Weight Watchers’ integrated care platform NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) - WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight health, today announced that eligible Weight Watchers Med+ members will have access to subscription pricing for Wegovy® that significantly reduces out-of-pocket costs and is a result of expanded collaboration between Weight Watchers and Novo Nordisk. The new subscription offer gives Weight Watchers Med+ members access to the lowest available self-pay price in the market for doses of Wegovy not otherwise available through limited-time offers, saving cash-pay members up to $1,200 per year. The announcement coincides with Novo Nordisk’s launch of the industry’s first-of-its-kind medication subscription pricing model

2025 Total Revenue and Adjusted EBITDA 1,2 above high end of previously provided guidance Total End of Period Subscribers of 2.8 million; End of Period Clinical Subscribers of 130 thousand, up 42% year-over-year with continued growth in first quarter 2026 Fourth Quarter Total Revenue of $163 million; Clinical Subscription Revenue of $27 million, up 32% year-over-year Fourth Quarter Net Loss of $6 million; Net Loss Margin of 3.6%; Adjusted EBITDA 1 of $18 million and Adjusted EBITDA Margin 1 of 11.1% Provides First Quarter 2026 End of Period Subscriber Estimates and Full Year 2026 Financial Guidance NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) - WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced its results for the fourth quarter and full year fiscal 2025 ended December 31, 2025 2 in this Earnings Press Release and a Shareholder Letter posted on the Company’s Corporate Website . “Our industry is

Weight Watchers’ Med+ members who regularly engaged with their GLP-1 Success Program lost up to 61% more body weight in the first month and 29% more in one year, on average, than those who took medication alone. Med+ members prescribed medication also reported, on average, over 30% more weight loss than select competitors at 12 months. NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) - WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight health, today released a GLP-1 Results Report which finds that individuals who take GLP-1 medications and regularly engage in the Weight Watchers GLP-1 Success Program achieved significantly greater weight loss and better health outcomes than those using medication alone. The Weight Watchers evidence review builds on a growing body of research on long-term weight management. For example, a recent systematic review published in the British Medical Journal found that weight regain commonly occurs after

NEW YORK, Feb. 27, 2026 (GLOBE NEWSWIRE) - WW International, Inc. (NASDAQ: WW) (“Weight Watchers” or the “Company”) will release its results for the fourth quarter and full year 2025 ended December 31, 2025 before market open on Monday, March 16, 2026. Weight Watchers will host a conference call to discuss results at 8:30 a.m. ET the same day. The webcast of the conference call will be available on the Company’s corporate website, corporate.ww.com , under Events and Presentations. A replay of the webcast will be available on this site for at least 90 days. About Weight Watchers Weight Watchers is the global leader in science-backed weight management, offering an integrated support system built for the GLP-1 era that combines scientific expertise, medication, cutting-edge technology, and human connection. With more than 60 years of experience, Weight Watchers is the most studied commercial weight management program in the world, delivered through its No. 1 U.S. doctor-recommended

The new partnership combines Weight Watchers’ scientifically-backed medical and behavioral expertise with PVOLVE’s clinically-studied method to support members at every age and stage of life NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) - WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight health, today announced a strategic partnership with PVOLVE , the clinically validated workout method, designed to support longevity through strength, mobility, and stability training. As weight health enters a new era driven by GLP-1 medications and growing awareness of the role lean muscle plays in metabolism, Weight Watchers continues to innovate its science-backed approach to deliver even stronger outcomes for members. Building and preserving muscle plays an important role in long-term health, especially for women in midlife and members using GLP-1 medications. To meet these evolving needs, Weight Watchers is further expanding its integrated approach by

NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) - WW International, Inc. (NASDAQ: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced that the Company will be participating in the following investor conferences in January: January 12-13, 2026: ICR Conference in Orlando, FL. The Company will host meetings with investors throughout the event. January 14, 2026: CJS Securities 26th Annual New Ideas for the New Year. The Company will be participating in a virtual fireside chat at 11:00 a.m. ET. The fireside chat will be accessible via live audio webcast on the Company’s corporate website, corporate.ww.com , under Events and Presentations. A replay of the webcast will be available on this site for at least 90 days. The Company will also host meetings with investors. ABOUT WEIGHT WATCHERS Weight Watchers is the global leader in science-backed weight management, offering an integrated support system built for the GLP-1 era

A NovoCare® Recognized Care Provider, Weight Watchers’ new Med+ program delivers an integrated GLP-1 care model proven to drive greater weight loss results than medication alone NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) - WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight health, today announced access to Novo Nordisk’s newly FDA approved oral formulation of Wegovy ® through its integrated GLP-1 platform. The addition of a once-daily Wegovy pill expands access to GLP-1 treatment and reinforces Weight Watchers’ leadership in delivering comprehensive care models that help people succeed on medication in real life by pairing medical therapy with evidence-based behavior change and ongoing support. Weight Watchers, through its affiliated Weight Watchers Clinic, is a NovoCare ® Recognized Care Provider based on its demonstrated ability to deliver FDA-approved GLP-1 medications alongside expert clinical care. Through Weight Watchers Med+ and